Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel

Molecular and Biochemical Parasitology

Volumn 173, Issue 1, 2010, Pages 25-31

  Kasinathan, Ravi S ^a   Morgan, William M ^a   Greenberg, Robert M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ABC transporter; ABCC1; Multidrug resistance; Multidrug resistance associated protein; Praziquantel; Schistosoma mansoni

Indexed keywords

ABC TRANSPORTER; ANTISCHISTOSOMAL AGENT; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PRAZIQUANTEL; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION TRANSPORT; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNOREACTIVITY; MALE; MAMMAL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SCHISTOSOMA MANSONI; SIGNAL TRANSDUCTION;

ANIMALS; ANTHELMINTICS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HELMINTH PROTEINS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PRAZIQUANTEL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

MAMMALIA; SCHISTOSOMA; SCHISTOSOMA MANSONI;

EID: 77953808820     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molbiopara.2010.05.003     Document Type: Article

References (59)

1. Hotez P.J., Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 2009, 3:e485.
2. van der Werf M.J., de Vlas S.J., Brooker S., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003, 86:125-139.
3. King C.H., Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn 2008, 4:65-79.
4. World Health Organization The global burden of disease, 2004 update 2008, World Health Organization, Geneva, Switzerland.
5. Kusel J.R., McVeigh P., Thornhill J.A. The schistosome excretory system: a key to regulation of metabolism, drug excretion and host interaction. Trends Parasitol 2009, 25:353-358.
6. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprote: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
7. Gimenez-Bonafe P., Guillen Canovas A., Ambrosio S., et al. Drugs modulating MDR. Multidrug resistance: biological and pharmaceutical advances in antitumour treatment 2008, 63-99. Research Signpost, Kerala, India. N.A. Colabufo (Ed.).
8. Johnstone R.W., Ruefli A.A., Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 2000, 25:1-6.
9. Yabe T., Suzuki N., Furukawa T., Ishihara T., Katsura I. Multidrug resistance-associated protein MRP-1 regulates dauer diapause by its export activity in Caenorhabditis elegans. Development 2005, 132:3197-3207.
10. Mizutani T., Masuda M., Nakai E., et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008, 9:167-174.
11. van de Ven R., Scheffer G.L., Scheper R.J., de Gruijl T.D. The ABC of dendritic cell development and function. Trends Immunol 2009, 30:421-429.
12. Blackhall W.J., Liu H.Y., Xu M., Prichard R.K., Beech R.N. Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Mol Biochem Parasitol 1998, 95:193-201.
13. Xu M., Molento M., Blackhall W., Ribeiro P., Beech R., Prichard R. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol Biochem Parasitol 1998, 91:327-335.
14. Sangster N.C., Bannan S.C., Weiss A.S., Nulf S.C., Klein R.D., Geary T.G. Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoproteins. Exp Parasitol 1999, 91:250-257.
15. Ardelli B.F., Guerriero S.B., Prichard R.K. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol 2005, 143:58-66.
16. Ardelli B.F., Guerriero S.B., Prichard R.K. Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in Onchocerca volvulus. Mol Biochem Parasitol 2006, 145:94-100.
17. Blackhall W.J., Prichard R.K., Beech R.N. P-glycoprotein selection in strains of Haemonchus contortus resistant to benzimidazoles. Vet Parasitol 2008, 152:101-107.
18. Kumkate S., Chunchob S., Janvilisri T. Expression of ATP-binding cassette multidrug transporters in the giant liver fluke Fasciola gigantica and their possible involvement in the transport of bile salts and anthelmintics. Mol Cell Biochem 2008, 317:77-84.
19. Bartley D.J., McAllister H., Bartley Y., et al. P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus. Parasitology 2009, 136:1081-1088.
20. Messerli S.M., Kasinathan R.S., Morgan W., Spranger S., Greenberg R.M. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol 2009, 167:54-59.
21. Kerboeuf D., Blackhall W., Kaminsky R., von Samson-Himmelstjerna G. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int J Antimicrob Agents 2003, 22:332-346.
22. Jones P.M., George A.M. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int J Parasitol 2005, 35:555-566.
23. Lespine A., Alvinerie M., Vercruysse J., Prichard R.K., Geldhof P. ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol 2008, 24:293-298.
24. James C.E., Hudson A.L., Davey M.W. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol 2009, 25:538-539.
25. James C.E., Hudson A.L., Davey M.W. Drug resistance mechanisms in helminths: is it survival of the fittest?. Trends Parasitol 2009, 25:328-335.
26. Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmacol Ther 1985, 29:129-156.
27. Cioli D., Pica-Mattoccia L. Praziquantel. Parasitol Res 2003, 90(Suppl. 1):S3-S9.
28. Zhang Y., Koukounari A., Kabatereine N., et al. Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med 2007, 5:27.
29. Toure S., Zhang Y., Bosque-Oliva E., et al. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso. Bull World Health Organ 2008, 86:780-787.
30. Xiao S.H., Catto B.A., Webster L.T. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 1985, 151:1130-1137.
31. Sabah A.A., Fletcher C., Webbe G., Doenhoff M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986, 61:294-303.
32. Pica-Mattoccia L., Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 2004, 34:527-533.
33. Redman C.A., Robertson A., Fallon P.G., et al. Praziquantel: an urgent and exciting challenge. Parasitol Today 1996, 12:14-20.
34. 2+ channels targets of praziquantel action?. Int J Parasitol 2005, 35:1-9.
35. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008, 21:659-667.
36. Day T.A., Botros S. Drug resistance in schistosomes. Parasitic flatworms: molecular biology, biochemistry, immunology and physiology 2006, 256-268. CAB International, Oxfordshire. A. Maule, N.J. Marks (Eds.).
37. Doenhoff M.J., Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther 2006, 4:199-210.
38. Bosch I.B., Wang Z.X., Tao L.F., Shoemaker C.B. Two Schistosoma mansoni cDNAs encoding ATP-binding cassette (ABC) family proteins. Mol Biochem Parasitol 1994, 65:351-356.
39. Kasinathan R.S., Goronga T., Messerli S.M., Webb T.R., Greenberg R.M. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J 2010, 24:128-135.
40. Kusel J.R., Oliveira F.A., Todd M., et al. The effects of drugs, ions, and poly-l-lysine on the excretory system of Schistosoma mansoni. Mem Inst Oswaldo Cruz 2006, 101(Suppl. 1):293-298.
41. Oliveira F.A., Kusel J.R., Ribeiro F., Coelho P.M. Responses of the surface membrane and excretory system of Schistosoma mansoni to damage and to treatment with praziquantel and other biomolecules. Parasitology 2006, 132:321-330.
42. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204:216-237.
43. Leier I., Jedlitschky G., Buchholz U., Cole S.P., Deeley R.G., Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994, 269:27807-27810.
44. Sato H., Kusel J.R., Thornhill J. Excretion of fluorescent substrates of mammalian multidrug resistance-associated protein (MRP) in the Schistosoma mansoni excretory system. Parasitology 2004, 128:43-52.
45. Lewis F.A. Schistosomiasis. Current protocols in immunology 1998, 19.1.1-19.1.28. Wiley Interscience, Hoboken (NJ). J.E. Coligan, Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., Coico R. (Eds.).
46. (T) method. Nat Protoc 2008, 3:1101-1108.
47. Jespersen T., Grunnet M., Angelo K., Klaerke D.A., Olesen S.P. Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes. Biotechniques 2002, 32:536-540.
48. Flens M.J., Izquierdo M.A., Scheffer G.L., et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994, 54:4557-4563.
49. Aragon A.D., Imani R.A., Blackburn V.R., et al. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 2009, 164:57-65.
50. Andrews P. Effect of praziquantel on the free living stages of Schistosoma mansoni. Z Parasitenkd 1978, 56:99-106.
51. Callaghan R., Crowley E., Potter S., Kerr I.D. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008, 48:365-378.
52. Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr Drug Targets 2001, 2:57-77.
53. Leslie E.M., Deeley R.G., Cole S.P. Toxicological relevance of the multidrug resistance protein 1. MRP1 (ABCC1) and related transporters. Toxicology 2001, 167:3-23.
54. Wijnholds J., Evers R., van Leusden M.R., et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997, 3:1275-1279.
55. Zhang J., Alston M.A., Huang H., Rabin R.L. Human T cell cytokine responses are dependent on multidrug resistance protein-1. Int Immunol 2006, 18:485-493.
56. Dong Y., Chollet J., Vargas M., et al. Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg Med Chem Lett 2010, 20:2481-2484.
57. Aller S.G., Yu J., Ward A., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
58. Hammond C.L., Marchan R., Krance S.M., Ballatori N. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J Biol Chem 2007, 282:14337-14347.
59. Marchan R., Hammond C.L., Ballatori N. Multidrug resistance-associated protein 1 as a major mediator of basal and apoptotic glutathione release. Biochim Biophys Acta 2008, 1778:2413-2420.